Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06009289 · ClinicalTrials.gov registry record · Phase 4
Light and Sleep Fragmentation
A Phase 4 study, sponsored by Stanford University.
- Not yet
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
NCT06009289: Clinical Trial Phase 4 study, sponsored by Stanford University.
NCT06009289 is a Phase 4 study that has not yet begun recruiting, run by Stanford University. The registered enrollment target is 120 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06009289, a Phase 4 study, has not yet begun recruiting, sponsored by Stanford University.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
Study Summary
This trial will examine scheduled exposure to bright light in the morning and afternoon as a countermeasure to sleep fragmentation in older individuals with mild cognitive impairment.
Primary Outcome
24 hour sleep wake patterns will be quantitated with a non-parametric measure, intradaily variation
Interventions
- BEHAVIORAL Light therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2028-05-30 |
| Phase | Phase 4 |
What is known before NCT06009289 opens enrollment
NCT06009289 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which Light therapy is the first listed.
NCT06009289 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06009289 about?
NCT06009289 is a clinical study titled "Light and Sleep Fragmentation". This trial will examine scheduled exposure to bright light in the morning and afternoon as a countermeasure to sleep fragmentation in older individuals with mild cognitive impairment.
What is the current status of trial NCT06009289?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2026-06-01. Estimated completion is 2028-05-30.
What interventions are being tested in trial NCT06009289?
The interventions under investigation include: Light therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT06009289?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06009289's enrollment target sits among peer trials
120 673rd of 2000 higher than 1,289 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI